Bio-Score™ ranks every biotech catalyst by predicted volatility magnitude — not direction. Know which FDA decisions, PDUFA dates, and clinical readouts are powder kegs before the move happens.
BioCatalysts.AI replaces scattered FDA calendars, Twitter rumors, and gut feel with an algorithmic signal ranked by what matters: how big the move will be.
Every upcoming biotech catalyst in one vertical scroll. Ranked by Bio-Score, not alphabetically. The highest-volatility events surface first — like a TikTok feed for catalysts.
Each catalyst gets a 0–150+ score predicting volatility magnitude. Above 150 is a "powder keg" — high probability of a major move, regardless of direction. The algorithm does the homework.
Tap into any catalyst for the full picture: price charts, SEC filings, clinical trial data, and curated news. Everything you need to size your position in one view.
Actual result: +46% overnight move ✓
Most tools try to predict if a stock will go up or down. That's a coin flip. Bio-Score measures something more useful: how volatile the catalyst event will be. A score of 168 doesn't say "buy" or "sell" — it says "this will move, and it will move big."
Built on three proprietary factors — Event Tier, Materiality, and Urgency — with exponential time decay and backtested against historical catalyst events.
Read the full methodology →Whether you're new to biotech trading or sharpening your edge, these guides break down the concepts that move this market.
PDUFA, NDA, BLA, AdCom, CRL — the alphabet soup decoded. Every term a biotech trader needs, explained without the jargon.
How the algorithm works, what the three factors measure, and why predicting magnitude beats predicting direction. With real case studies.
Not all catalysts are created equal. Learn the tier system, what makes a catalyst "high confidence," and how to read the signals.
| Ticker | Event | Bio-Score | Date |
|---|---|---|---|
| XENE | PDUFA — Azetukalner | 168 | Sample |
| VNDA | PDUFA — Tradipitant | 150 | Sample |
| CARA | PDUFA — Korsuva | 150 | Sample |
| ACAD | Phase 3 Readout | 132 | - |
| IONS | NDA Decision | 127 | - |
The macro trends shaping catalyst outcomes — from regulatory shifts to therapeutic area momentum. Updated regularly.
Explore themes →Join the Founder's Club and get early access to Bio-Score™ powered catalyst intelligence. Wall Street intelligence. Retail pricing.
Open App →